March 2, 2017
Changes in Lilly executive committee
Eli Lilly’s senior vice president of global quality Fionnuala Walshis retiring after almost three decades at the company. Her replacement will be
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
March 2, 2017
PureTech Health gets new strategist to help CEO
PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.
March 1, 2017
Forward Pharma puts new CEO to reduce burn rate after $1.25 billion settlement with Biogen
Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.
March 1, 2017
Lilly buys CoLucid Pharmaceuticals
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.
March 1, 2017
FDA approves orphan drug Xermelo for frequent, severe diarrhea
The U.S. Food and Drug Administration (FDA) approved Lexicon Pharmaceuticals’ Xermelo tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone couldn’t control properly.
March 1, 2017
Amaran Biotechnology picks Stellar KLH for cancer vaccines
Stellar Biotechnologies and biopharmaceuticals manufacturer Amaran Biotechnology have entered into an exclusive multi-year supply agreement regarding studies of immunotherapies for various cancers, including breast cancer.
March 1, 2017
Novartis cancer division races to catch up with rivals
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview
March 1, 2017
Orexo AB files patent violation against Teva’s Actavis in US
Another patent infringement against Teva has been filed in recent couple of months. Orexo AB has filed a patent infringement action in United States District Court for the District of Delaware against Actavis Elizabeth LLC, Actavis Pharma, Inc., and their parent company Teva.
March 1, 2017
Novo Nordisk’s vice president, head of North America leaves
Novo Nordisk’s executive vice president, head of North America Operations and president of Novo Nordisk Inc. Jakob Riis has resigned from the company, and will be replaced by senior vice president for Market Access, Doug Langa.
March 1, 2017
Unioversity College London develops anti-phospholipid syndrome treatment with Abzena’s technology, gets £3.5m grant from the Medical Research Council
A research group from University College London’s (UCL’s) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to continue developing of a new treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.